DS
HALO icon

David Shaw’s Halozyme HALO Stock Holding History

David Shaw’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Buy
28,200
+7,300
+35% +$498K ﹤0.01% 3117
2026
Q1 		$1.35M Buy
+20,900
New +$1.47M ﹤0.01% 3205
2015
Q2 		– Sell
-53,000
Closed -$757K – 3783
2015
Q1 		$757K Buy
+53,000
New +$764K ﹤0.01% 2766

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

David Shaw's HALO Position: Q2 2026 in Review

David Shaw increased its Halozyme (HALO) stake by 7.4% in Q2 2026, buying an estimated $9.39M and bringing the position to 2,006,479 shares worth $157M. The position accounts for 0.07% of the portfolio, ranked #278.

David Shaw first reported a position in HALO in Q1 2014 and has held it in 47 quarters since. The position peaked at $194M in Q3 2025. 665 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • David Shaw held 2,006,479 shares of Halozyme worth $157M as of Q2 2026.
  • David Shaw bought 137,771 Halozyme shares in Q2 2026, an estimated $9.39M.
  • Halozyme made up 0.07% of David Shaw's portfolio in Q2 2026, its #278 holding.
  • David Shaw first reported a position in Halozyme in Q1 2014 and has held it in 47 quarters since.
  • David Shaw's Halozyme position peaked at $194M in Q3 2025.
  • 665 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.